The Health Wonk Shop KFF

A panel of primary-care experts joined Larry Levitt, KFF’s executive vice president for health policy, for a discussion on the current state of primary care in the country, including the extent of the shortage, how it varies geographically and for different populations, the impact on people’s health, and what can be done to address it.
Hosted on Acast. See acast.com/privacy for more information.

Nearly 1 in 5 consumers with health insurance say their insurer delayed or denied care in the past year due to its requirements for prior authorization, a process through which insurers can require patients to obtain approval in advance before they will agree to cover specific services.
Insurers point to prior authorization as a tool to limit unnecessary and ineffective care, thereby reducing costs. However, the practice is also drawing increased scrutiny amid concerns that it creates unreasonable barriers to patients getting needed care and generates excessive paperwork burdens on doctors and other providers. Last month, federal regulators finalized new rules to govern how insurers use prior authorization in Medicare Advantage, Medicaid, the Children’s Health Insurance Program, and the Affordable Care Act’s federal Marketplace plans, while lawmakers are weighing potential broader legislation.
On February 22, a panel of four experts joined Larry Levitt, KFF’s executive vice president for health policy, for a 45-minute discussion addressing the future of prior authorization requirements in health care. The panel discussed why insurers use prior authorization, its impact on patients and providers, and how the new regulations may change current practices. They also examined the potential for further regulatory or legislative actions to address ongoing concerns.
Moderator
Larry Levitt, Executive Vice President for Health Policy, KFF
Panelists
Troyen Brennan, MD, Adjunct Professor of Health Policy and Management, Harvard T.H. Chan School of Public Health, and a former executive at CVS Caremark and AetnaFumiko Chino, MD, Radiation Oncologist, Memorial Sloan Kettering Cancer CenterAnna Schwamlein Howard, Principal, Policy Development, American Cancer Society Cancer Action NetworkKaye Pestaina, Vice President and Director of the Program on Patient and Consumer Protection, KFF

Hosted on Acast. See acast.com/privacy for more information.

Amid low unemployment and rising demand for services, today’s health care workforce is under pressure from several directions, including worker strikes; shortages of trained staff; and proposed new staffing standards for nurses and aides in nursing facilities.
On November 16, a panel of three experts joined Larry Levitt, executive vice president for health policy at KFF, for a 45-minute discussion focused on the diverse challenges facing the health care workforce. The conversation touched on why and where there are worker shortages, what is driving recent strikes, how these pressures affect health systems, and how the proposed new staffing requirements could affect nursing homes. The panel also explored differences in rural and urban settings, and how the pandemic and other factors have increased burnout among health care workers.
Moderator
Larry Levitt, Executive Vice President for Health Policy, KFF
Panelists
Gretchen Berlin, Senior Partner, McKinsey & CompanyAlice Burns, Associate Director of the Program on Medicaid and the Uninsured, KFFBianca K. Frogner, Director of the University of Washington’s Center for Health Workforce Studies, and Professor in UW’s Department of Family Medicine
KFF’s virtual Health Wonk Shop series features in-depth policy discussions with experts that go beyond the news headlines to provide greater insights.

Hosted on Acast. See acast.com/privacy for more information.

With the Biden administration’s announcement of the first 10 drugs to be negotiated for Medicare as part of the Inflation Reduction Act (IRA), an array of legal challenges from the pharmaceutical industry is potentially the biggest obstacle to implementation.
In court filings, individual drugmakers and the industry’s main lobbying group contend that the negotiations process is unconstitutional in a variety of ways, from violating freedom of speech to unlawful government seizure and excessive fines. They also continue to argue, as they did in the debate over the IRA, that requiring companies to negotiate the prices of drugs with the government will impede the development of new drugs.
On Tuesday, September 12, two legal experts and a health policy expert joined Larry Levitt, executive vice president for health policy at KFF, for a 45-minute discussion about the legal issues underpinning these lawsuits and how they intersect with the policy goals of the legislation.
 
Moderator
Larry Levitt, Executive Vice President for Health Policy, KFFPanelists
Zachary Baron, Associate Director, Health Policy and the Law Initiative at the O’Neill Institute for National and Global Health Law at Georgetown University.Tricia Neuman, Senior Vice President and Executive Director of the Program on Medicare Policy, KFFDan Troy, Managing Director, Berkeley Research Group 
KFF’s virtual Health Wonk Shop series features in-depth policy discussions with experts that go beyond the news headlines to provide greater insights.

Hosted on Acast. See acast.com/privacy for more information.

New weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide), could be transformative for people who struggle with obesity and obesity-related medical conditions, but there are major questions to consider related to insurance coverage, the cost of the drugs, and who has access.
Importantly, by law, the drugs cannot be covered by Medicare for weight loss and are often covered now by private insurers in limited circumstances. Manufacturers of the drugs are lobbying for broad coverage by Medicare and other payers.
On August 4, three experts joined Larry Levitt, executive vice president for health policy at KFF, for a 45-minute “Health Wonk Shop” discussion about the questions surrounding what a new generation of weight loss drugs means for patients and payers:
Who could benefit most from the new weight loss drugs, and what are the barriers to accessing them?What would be the impact of Congress overturning the prohibition on Medicare covering weight loss drugs?How are employers and insurers approaching coverage of the drugs given the potentially substantial costs involved?What are the broader implications of the new drugs for U.S. obesity rates and for national health spending, including on obesity-related health conditions?
Moderator
Larry Levitt, Executive Vice President for Health Policy, KFF
Panelists
Juliette Cubanski, PhD, Deputy Director, Program on Medicare Policy at KFFShauna Levy, MD, MS, Assistant Professor, Division of MIS/Bariatric Surgery, Tulane University School of MedicineMichael Manolakis, PharmD, PhD, Senior Vice President, Pharmacy, Aon 
KFF’s virtual Health Wonk Shop series features in-depth policy discussions with experts that go beyond the news headlines to provide greater insights.

Hosted on Acast. See acast.com/privacy for more information.

Pharmacy benefit managers (PBMs) are increasingly scrutinized intermediaries in the U.S. health care system, negotiating discounts on prescription medications for health insurers and employers while collecting rebates from drugmakers.
Even as PBMs have taken on a larger role in drug coverage and pricing in recent decades, including through mergers with insurers, the business arrangements that shape their finances remain unusually opaque. That has led to questions about the role PBMs play in the rising cost of prescription drugs, investigations by Congress and the Federal Trade Commission into PBMs business practices, and federal and state efforts to regulate those practices and require greater transparency.
On June 14, two experts joined KFF’s The Health Wonk Shop and series moderator Larry Levitt in a 45-minute discussion about the power and practices of PBMs, addressing such questions as:
How do PBMs make money?What role do PBMs have in drug costs?What legislation or other reforms are being considered, and how would they affect consumers? 
Moderator
Larry Levitt, Executive Vice President for Health Policy, KFF
Panelists
Jennifer Reck, Director, Center on Drug Pricing, National Academy for State Health PolicyKaren Van Nuys, Executive Director of the Value of Life Sciences Innovation Program and Senior Fellow, University of Southern California Schaeffer Center for Health Policy and Economics 
KFF’s virtual Health Wonk Shop series features in-depth policy discussions with experts that go beyond the news headlines to provide greater insights.


Hosted on Acast. See acast.com/privacy for more information.